FDA turns away filing for Celgene’s MS drug
admin 1st March 2018 Uncategorised 0US regulators are refusing to file Celgene’s application to market its experimental multiple sclerosis therapy ozanimod.
More: FDA turns away filing for Celgene’s MS drug
Source: News